Antipsychotic drugs antagonise human serotonin type 3 (5-HT ) receptor currents in a noncompetitive manner
The serotonin type 3 (5-HT(3)) receptor is the only ligand-gated ion channel receptor for serotonin (5-HT). 5-HT(3) receptors play an important role in modulating the inhibitory action of dopamine in mesocorticolimbic brain regions. Neuroleptic drugs are commonly thought to exert their psychopharmac...
Gespeichert in:
Veröffentlicht in: | Molecular psychiatry 2004-09, Vol.9 (9), p.818-818 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 818 |
---|---|
container_issue | 9 |
container_start_page | 818 |
container_title | Molecular psychiatry |
container_volume | 9 |
creator | Rammes, G Eisensamer, B Ferrari, U Shapa, M Gimpl, G Gilling, K Parsons, C Riering, K Hapfelmeier, G Bondy, B Zieglgänsberger, W Holsboer, F Rupprecht, R |
description | The serotonin type 3 (5-HT(3)) receptor is the only ligand-gated ion channel receptor for serotonin (5-HT). 5-HT(3) receptors play an important role in modulating the inhibitory action of dopamine in mesocorticolimbic brain regions. Neuroleptic drugs are commonly thought to exert their psychopharmacological action mainly through dopamine and serotonin type 2 (5-HT(2)) receptors. Except for clozapine, a direct pharmacological interaction of neuroleptics with 5-HT(3) receptors has not yet been described. Using the concentration-clamp technique, we investigated the effects of flupentixol, various phenothiazines, haloperidol, clozapine and risperidone on Na(+)-inward currents through 5-HT(3) receptors stably expressed in human embryonic kidney 293 cells, and through endogenous 5-HT(3) receptors of murine N1E-115 neuroblastoma cells. In addition, we studied their effects on Ca(2+) influx, measured as a change in intracellular Ca(2+) concentrations ([Ca(2+)](i)). All neuroleptic drugs, but not risperidone, antagonized Na(+)- and Ca(2+)-inward currents evoked by 5-HT (10 microM for 2 s and 1 microM, respectively) in a voltage-independent manner. Only clozapine was a competitive antagonist, while all other compounds turned out to be noncompetitive. Fluphenazine and haloperidol affected membrane anisotropy at concentrations below their IC(50) values, indicating that a change in membrane anisotropy might contribute to their antagonistic effect at the 5-HT(3) receptor. Only structure analogues of flupentixol and fluphenazine with a lipophilic side chain were potent antagonists against 5-HT-evoked Na(+) and Ca(2+) currents. Since 5-HT(3) receptors modulate mesolimbic and mesocortical dopaminergic activity, the functional antagonism of neuroleptics at 5-HT(3) receptors may contribute to their antipsychotic efficacy and may constitute a not yet recognized pharmacological principle of these drugs. |
doi_str_mv | 10.1038/sj.mp.4001567 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66822129</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>984488431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c258t-571cbb312944f17b20abeb1ecd51de428701ccdae8d04050e03923eb67e95bcb3</originalsourceid><addsrcrecordid>eNp10UFLwzAUwPEiCs7p0aMQFEQPnUmatOlxDHXCwMs8hzR921rWpCapsG9vxqYHwVNC3o8_gZck1wRPCM7Ek28nXT9hGBOeFyfJiLAiTzkvxGm8Z7xMGRHsPLnwvo0mDvkoaacmNL3f6Y0NjUa1G9YeKRPU2prGA9oMnTLIg7MhPhgUdj2gDD3wdL5Ej8iBhj5Yh_TgHJjgUTQKGWu07XoITWi-AMWEAXeZnK3U1sPV8RwnHy_Py9k8Xby_vs2mi1RTLkLKC6KrKiO0ZGxFiopiVUFFQNec1MCoKDDRulYgaswwx4CzkmZQ5QWUvNJVNk7uD93e2c8BfJBd4zVst8qAHbzMc0FpzEd49we2dnAm_k3SnPGCZ5iKqG7_VTHDhCj3qfSAtLPeO1jJ3jWdcjtJsNwvR_pWdr08Lif6m4M3KgwOfvXP_BvYVoyV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>221248899</pqid></control><display><type>article</type><title>Antipsychotic drugs antagonise human serotonin type 3 (5-HT ) receptor currents in a noncompetitive manner</title><source>Alma/SFX Local Collection</source><creator>Rammes, G ; Eisensamer, B ; Ferrari, U ; Shapa, M ; Gimpl, G ; Gilling, K ; Parsons, C ; Riering, K ; Hapfelmeier, G ; Bondy, B ; Zieglgänsberger, W ; Holsboer, F ; Rupprecht, R</creator><creatorcontrib>Rammes, G ; Eisensamer, B ; Ferrari, U ; Shapa, M ; Gimpl, G ; Gilling, K ; Parsons, C ; Riering, K ; Hapfelmeier, G ; Bondy, B ; Zieglgänsberger, W ; Holsboer, F ; Rupprecht, R</creatorcontrib><description>The serotonin type 3 (5-HT(3)) receptor is the only ligand-gated ion channel receptor for serotonin (5-HT). 5-HT(3) receptors play an important role in modulating the inhibitory action of dopamine in mesocorticolimbic brain regions. Neuroleptic drugs are commonly thought to exert their psychopharmacological action mainly through dopamine and serotonin type 2 (5-HT(2)) receptors. Except for clozapine, a direct pharmacological interaction of neuroleptics with 5-HT(3) receptors has not yet been described. Using the concentration-clamp technique, we investigated the effects of flupentixol, various phenothiazines, haloperidol, clozapine and risperidone on Na(+)-inward currents through 5-HT(3) receptors stably expressed in human embryonic kidney 293 cells, and through endogenous 5-HT(3) receptors of murine N1E-115 neuroblastoma cells. In addition, we studied their effects on Ca(2+) influx, measured as a change in intracellular Ca(2+) concentrations ([Ca(2+)](i)). All neuroleptic drugs, but not risperidone, antagonized Na(+)- and Ca(2+)-inward currents evoked by 5-HT (10 microM for 2 s and 1 microM, respectively) in a voltage-independent manner. Only clozapine was a competitive antagonist, while all other compounds turned out to be noncompetitive. Fluphenazine and haloperidol affected membrane anisotropy at concentrations below their IC(50) values, indicating that a change in membrane anisotropy might contribute to their antagonistic effect at the 5-HT(3) receptor. Only structure analogues of flupentixol and fluphenazine with a lipophilic side chain were potent antagonists against 5-HT-evoked Na(+) and Ca(2+) currents. Since 5-HT(3) receptors modulate mesolimbic and mesocortical dopaminergic activity, the functional antagonism of neuroleptics at 5-HT(3) receptors may contribute to their antipsychotic efficacy and may constitute a not yet recognized pharmacological principle of these drugs.</description><identifier>ISSN: 1359-4184</identifier><identifier>EISSN: 1476-5578</identifier><identifier>DOI: 10.1038/sj.mp.4001567</identifier><language>eng</language><publisher>New York: Nature Publishing Group</publisher><subject>Antipsychotics ; Serotonin S3 receptors</subject><ispartof>Molecular psychiatry, 2004-09, Vol.9 (9), p.818-818</ispartof><rights>Copyright Nature Publishing Group Sep 2004</rights><rights>Nature Publishing Group 2004.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c258t-571cbb312944f17b20abeb1ecd51de428701ccdae8d04050e03923eb67e95bcb3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids></links><search><creatorcontrib>Rammes, G</creatorcontrib><creatorcontrib>Eisensamer, B</creatorcontrib><creatorcontrib>Ferrari, U</creatorcontrib><creatorcontrib>Shapa, M</creatorcontrib><creatorcontrib>Gimpl, G</creatorcontrib><creatorcontrib>Gilling, K</creatorcontrib><creatorcontrib>Parsons, C</creatorcontrib><creatorcontrib>Riering, K</creatorcontrib><creatorcontrib>Hapfelmeier, G</creatorcontrib><creatorcontrib>Bondy, B</creatorcontrib><creatorcontrib>Zieglgänsberger, W</creatorcontrib><creatorcontrib>Holsboer, F</creatorcontrib><creatorcontrib>Rupprecht, R</creatorcontrib><title>Antipsychotic drugs antagonise human serotonin type 3 (5-HT ) receptor currents in a noncompetitive manner</title><title>Molecular psychiatry</title><description>The serotonin type 3 (5-HT(3)) receptor is the only ligand-gated ion channel receptor for serotonin (5-HT). 5-HT(3) receptors play an important role in modulating the inhibitory action of dopamine in mesocorticolimbic brain regions. Neuroleptic drugs are commonly thought to exert their psychopharmacological action mainly through dopamine and serotonin type 2 (5-HT(2)) receptors. Except for clozapine, a direct pharmacological interaction of neuroleptics with 5-HT(3) receptors has not yet been described. Using the concentration-clamp technique, we investigated the effects of flupentixol, various phenothiazines, haloperidol, clozapine and risperidone on Na(+)-inward currents through 5-HT(3) receptors stably expressed in human embryonic kidney 293 cells, and through endogenous 5-HT(3) receptors of murine N1E-115 neuroblastoma cells. In addition, we studied their effects on Ca(2+) influx, measured as a change in intracellular Ca(2+) concentrations ([Ca(2+)](i)). All neuroleptic drugs, but not risperidone, antagonized Na(+)- and Ca(2+)-inward currents evoked by 5-HT (10 microM for 2 s and 1 microM, respectively) in a voltage-independent manner. Only clozapine was a competitive antagonist, while all other compounds turned out to be noncompetitive. Fluphenazine and haloperidol affected membrane anisotropy at concentrations below their IC(50) values, indicating that a change in membrane anisotropy might contribute to their antagonistic effect at the 5-HT(3) receptor. Only structure analogues of flupentixol and fluphenazine with a lipophilic side chain were potent antagonists against 5-HT-evoked Na(+) and Ca(2+) currents. Since 5-HT(3) receptors modulate mesolimbic and mesocortical dopaminergic activity, the functional antagonism of neuroleptics at 5-HT(3) receptors may contribute to their antipsychotic efficacy and may constitute a not yet recognized pharmacological principle of these drugs.</description><subject>Antipsychotics</subject><subject>Serotonin S3 receptors</subject><issn>1359-4184</issn><issn>1476-5578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp10UFLwzAUwPEiCs7p0aMQFEQPnUmatOlxDHXCwMs8hzR921rWpCapsG9vxqYHwVNC3o8_gZck1wRPCM7Ek28nXT9hGBOeFyfJiLAiTzkvxGm8Z7xMGRHsPLnwvo0mDvkoaacmNL3f6Y0NjUa1G9YeKRPU2prGA9oMnTLIg7MhPhgUdj2gDD3wdL5Ej8iBhj5Yh_TgHJjgUTQKGWu07XoITWi-AMWEAXeZnK3U1sPV8RwnHy_Py9k8Xby_vs2mi1RTLkLKC6KrKiO0ZGxFiopiVUFFQNec1MCoKDDRulYgaswwx4CzkmZQ5QWUvNJVNk7uD93e2c8BfJBd4zVst8qAHbzMc0FpzEd49we2dnAm_k3SnPGCZ5iKqG7_VTHDhCj3qfSAtLPeO1jJ3jWdcjtJsNwvR_pWdr08Lif6m4M3KgwOfvXP_BvYVoyV</recordid><startdate>200409</startdate><enddate>200409</enddate><creator>Rammes, G</creator><creator>Eisensamer, B</creator><creator>Ferrari, U</creator><creator>Shapa, M</creator><creator>Gimpl, G</creator><creator>Gilling, K</creator><creator>Parsons, C</creator><creator>Riering, K</creator><creator>Hapfelmeier, G</creator><creator>Bondy, B</creator><creator>Zieglgänsberger, W</creator><creator>Holsboer, F</creator><creator>Rupprecht, R</creator><general>Nature Publishing Group</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>200409</creationdate><title>Antipsychotic drugs antagonise human serotonin type 3 (5-HT ) receptor currents in a noncompetitive manner</title><author>Rammes, G ; Eisensamer, B ; Ferrari, U ; Shapa, M ; Gimpl, G ; Gilling, K ; Parsons, C ; Riering, K ; Hapfelmeier, G ; Bondy, B ; Zieglgänsberger, W ; Holsboer, F ; Rupprecht, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c258t-571cbb312944f17b20abeb1ecd51de428701ccdae8d04050e03923eb67e95bcb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Antipsychotics</topic><topic>Serotonin S3 receptors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rammes, G</creatorcontrib><creatorcontrib>Eisensamer, B</creatorcontrib><creatorcontrib>Ferrari, U</creatorcontrib><creatorcontrib>Shapa, M</creatorcontrib><creatorcontrib>Gimpl, G</creatorcontrib><creatorcontrib>Gilling, K</creatorcontrib><creatorcontrib>Parsons, C</creatorcontrib><creatorcontrib>Riering, K</creatorcontrib><creatorcontrib>Hapfelmeier, G</creatorcontrib><creatorcontrib>Bondy, B</creatorcontrib><creatorcontrib>Zieglgänsberger, W</creatorcontrib><creatorcontrib>Holsboer, F</creatorcontrib><creatorcontrib>Rupprecht, R</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rammes, G</au><au>Eisensamer, B</au><au>Ferrari, U</au><au>Shapa, M</au><au>Gimpl, G</au><au>Gilling, K</au><au>Parsons, C</au><au>Riering, K</au><au>Hapfelmeier, G</au><au>Bondy, B</au><au>Zieglgänsberger, W</au><au>Holsboer, F</au><au>Rupprecht, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antipsychotic drugs antagonise human serotonin type 3 (5-HT ) receptor currents in a noncompetitive manner</atitle><jtitle>Molecular psychiatry</jtitle><date>2004-09</date><risdate>2004</risdate><volume>9</volume><issue>9</issue><spage>818</spage><epage>818</epage><pages>818-818</pages><issn>1359-4184</issn><eissn>1476-5578</eissn><abstract>The serotonin type 3 (5-HT(3)) receptor is the only ligand-gated ion channel receptor for serotonin (5-HT). 5-HT(3) receptors play an important role in modulating the inhibitory action of dopamine in mesocorticolimbic brain regions. Neuroleptic drugs are commonly thought to exert their psychopharmacological action mainly through dopamine and serotonin type 2 (5-HT(2)) receptors. Except for clozapine, a direct pharmacological interaction of neuroleptics with 5-HT(3) receptors has not yet been described. Using the concentration-clamp technique, we investigated the effects of flupentixol, various phenothiazines, haloperidol, clozapine and risperidone on Na(+)-inward currents through 5-HT(3) receptors stably expressed in human embryonic kidney 293 cells, and through endogenous 5-HT(3) receptors of murine N1E-115 neuroblastoma cells. In addition, we studied their effects on Ca(2+) influx, measured as a change in intracellular Ca(2+) concentrations ([Ca(2+)](i)). All neuroleptic drugs, but not risperidone, antagonized Na(+)- and Ca(2+)-inward currents evoked by 5-HT (10 microM for 2 s and 1 microM, respectively) in a voltage-independent manner. Only clozapine was a competitive antagonist, while all other compounds turned out to be noncompetitive. Fluphenazine and haloperidol affected membrane anisotropy at concentrations below their IC(50) values, indicating that a change in membrane anisotropy might contribute to their antagonistic effect at the 5-HT(3) receptor. Only structure analogues of flupentixol and fluphenazine with a lipophilic side chain were potent antagonists against 5-HT-evoked Na(+) and Ca(2+) currents. Since 5-HT(3) receptors modulate mesolimbic and mesocortical dopaminergic activity, the functional antagonism of neuroleptics at 5-HT(3) receptors may contribute to their antipsychotic efficacy and may constitute a not yet recognized pharmacological principle of these drugs.</abstract><cop>New York</cop><pub>Nature Publishing Group</pub><doi>10.1038/sj.mp.4001567</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1359-4184 |
ispartof | Molecular psychiatry, 2004-09, Vol.9 (9), p.818-818 |
issn | 1359-4184 1476-5578 |
language | eng |
recordid | cdi_proquest_miscellaneous_66822129 |
source | Alma/SFX Local Collection |
subjects | Antipsychotics Serotonin S3 receptors |
title | Antipsychotic drugs antagonise human serotonin type 3 (5-HT ) receptor currents in a noncompetitive manner |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T04%3A38%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antipsychotic%20drugs%20antagonise%20human%20serotonin%20type%203%20(5-HT%20)%20receptor%20currents%20in%20a%20noncompetitive%20manner&rft.jtitle=Molecular%20psychiatry&rft.au=Rammes,%20G&rft.date=2004-09&rft.volume=9&rft.issue=9&rft.spage=818&rft.epage=818&rft.pages=818-818&rft.issn=1359-4184&rft.eissn=1476-5578&rft_id=info:doi/10.1038/sj.mp.4001567&rft_dat=%3Cproquest_cross%3E984488431%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=221248899&rft_id=info:pmid/&rfr_iscdi=true |